Prior Authorization: Delivered Dose and Safety Monitoring

Prior authorization is required and must include documentation of the delivered dialysis dose and device-specific safety monitoring data. Provide objective efficacy and safety endpoints from the home hemodialysis trial or program used (for example, weekly standard Kt/Vurea, delivered ultrafiltration compared to prescribed UF, and description of any prespecified adverse events and relatedness). Include evidence that the individual met trial endpoints or monitoring thresholds used to assess device or regimen performance.

• Document weekly standard Kt/Vurea (e.g., target ≥ 2.1 when applicable) and/or per-protocol efficacy metric used by the device or program
• Report UF delivery accuracy (e.g., achieved UF within ±10% of prescribed UF) and frequency of missed/partial UF deliveries
• List prespecified adverse events observed during home treatments and note any events attributed to the device or home setting, with severity and outcome details
• Include training completion documentation (CPT 90989 or 90993 where applicable), patient/caregiver competency assessments, and note if home visit (CPT 99512) or home therapy per-diem (S9335) services are used

Verify Applicable Codes and Prior Authorization

Reviewers and providers must verify that the codes submitted match current payer requirements and that removed CPT codes are not used. If coverage criteria are not met or required monitoring/documentation is absent, prior authorization may be denied and claims may be subject to coding/billing risk.

• Do not submit removed CPT codes (see Policy History for removed codes such as 90963–90969)
• Confirm use of applicable ESRD/monthly or per-diem codes (e.g., 90966, 90970) and training codes (90989, 90993) as appropriate
• Ensure prior authorization request references the clinical documentation of delivered dose and safety monitoring

Required Clinical Documentation and Denial Triggers

Provide required clinical documentation demonstrating suitability for home hemodialysis and safety of the proposed therapy. Required materials should show stability on dialysis, completion of training, caregiver capability when applicable, and device-specific monitoring results. Lack of these documents is a common trigger for denial.

• Evidence of stability on dialysis without need for skilled interventions during treatments
• Training completion record (CPT 90989 for completed course or 90993 per session if course not completed) and competency assessment of patient and caregiver
• Clinical notes addressing absence of contraindicating comorbidities and confirming well-functioning vascular access
• Device- or program-specific monitoring logs (Kt/V, UF delivery, adverse events) used to support safety and efficacy

Recommended Trial Endpoints to Document

When prior authorization or clinical review is performed, document recommended trial endpoints and monitoring thresholds used to evaluate home hemodialysis safety and efficacy. These metrics support clinical decision-making and authorization determinations.

• Weekly standard Kt/Vurea (example target ≥ 2.1 where device-specific evidence supports this threshold)
• Ultrafiltration delivery within ±10% of prescribed UF for a defined proportion of treatments (e.g., ≥ 90% of treatments during trial period)
• Prespecified adverse events with counts, severity, and relatedness to device or home setting; specify trial period duration and measurement frequency

Policy Use and Documentation

This policy is informational and must be applied in the context of the member’s federal, state, or contractual benefit plan terms. Reviewers should reference applicable benefit terms and any third-party utilization criteria (e.g., InterQual) when making coverage determinations.

• Check federal, state, and contractual benefit language before relying solely on this policy
• Document rationale for coverage decisions in the medical record and prior authorization notes
• Use current payer and third-party criteria tools as applicable